As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
Despite a steady stream of hype and "pockets" of change, most cardiologists aren’t seeing the transformation that Silicon Valley promised. ACC CIO John Rumsfeld, MD, PhD, explains what's missing and why engaging clinical partners could help.
Multidisciplinary teams are leveraging advanced technologies to explore the link between cardiovascular disease and dementia with an eye toward improving the diagnosis and treatment of both.
In this first magazine of the 2020s, CVB invites the cardiology community to consider new mindsets for a number of areas, from treating dementias to tackling authorizations, documentation and collections.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of MiniMed Connect, the first and only product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitoring (CGM) information on a smartphone.
LOS ANGELES (March 27, 2014) – Two Cedars-Sinai Heart Institute physician-researchers have been named recipients of prestigious awards from the American College of Cardiology.
More than 2,000 experts in the field of cardiology will join together at this year's three-day American College of Cardiology 46th New York Cardiovascular Symposium from December 13-15 in New York City. The event, which is one of the most prestigious cardiology events in the world, will review and highlight the latest advances in cardiology for 2013 and the next big things to expect in cardiology in 2014.
Gov. Rick Perry today announced a $3 million investment through the Texas Emerging Technology Fund (TETF) to create the Center for Cell and Organ Biotechnology in collaboration with the Texas Heart Institute (THI) and Texas A&M University College of Veterinary Medicine and Biomedical Sciences.
NEW ORLEANSThe much-anticipated results of the JUPITER study show that rosuvastatin (Crestor) significantly reduced the incidence of cardiovascular events in healthy people who do not have high cholesterol but have elevated high-sensitivity C-reactive protein levels (test that measures inflammation). The study was presented Sunday in the late-breaking clinical trials at the American Heart Association (AHA) Scientific Sessions, and simultaneously published in the New England Journal of Medicine (NEJM).
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
